Eli Lilly plans to launch weight-loss drug in emerging markets this year
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
Is Eli Lilly Stock a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Ozempic maker says its Australian market could be half the population
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
Is the obesity drug market still a duopoly?
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
The Motley Fool27d
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...
USA Today16d
Eli Lilly will build 4 new manufacturing sites to increase domestic drug production
Eli Lilly and Co. Wednesday announced plans to build four pharmaceutical manufacturing sites in the United States, significantly boosting domestic medicine production and adding around 13,000 ...
AOL12d
Where Will Eli Lilly Be in 5 Years?
It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...